BrainStorm promotes Bob Dagher to Chief Medical Officer

BrainStorm Cell Therapeutics announced the promotion of Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four years of maintaining top executive roles, Stacy Lindborg stepping down from the role of Co-CEO and will remain with BrainStorm as a member of its Board of Directors. These strategic management changes are being made as the Company prepares to embark on a registrational Phase 3b trial for NurOwn(R), its investigational cell therapy treatment for amyotrophic lateral sclerosis, or ALS. Dagher has served as our Chief Development Officer since July 2023. In his new role as Executive Vice President and Chief Medical Officer, Dr. Dagher’s responsibilities will include overseeing the planned Phase 3b registration trial of NurOwn. The Company recently announced that it has reached agreement with the FDA for a Special Protocol Assessment for this trial.